Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028", is projected to reach USD 19.0 billion by 2028 from USD 13.2 billion in 2023, at a CAGR of 7.5% during the forecast period. Growth in the chemiluminescence immunoassay market is mainly driven by the growing prevalence of chronic diseases, Advancements in improving chemiluminescence immunoassay technologies in recent years, rising demand for point-of-care testing (POCT), growth of biotechnology and biopharmaceutical industries, and a rapid increase in geriatric population globally. In addition, emerging markets such as India and China are expected to offer growth opportunities for players operating in the chemiluminescence immunoassay market during the forecast period. However, the high cost of CLIA systems is restricting the growth of this market.Top of Form
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131865271
Browse in-depth TOC on "Chemiluminescence Immunoassay Market"
181 - Tables
52 - Figures
283 – Pages
Key Market Players:
The CLIA market is moderately competitive, with certain companies holding substantial market shares. The prominent players in chemiluminescence immunoassay market are Danaher Corporation (US), Siemens Healthineers AG (Germany), and F. Hoffmann-La Roche AG (Switzerland). Companies adopt organic and inorganic growth strategies such as product launches & approvals, expansions, and partnerships to increase their product offerings and expand their presence in the global CLIA market.
In 2022, the consumables segment held the largest share of the chemiluminescence market, by product segment
Based on product, the global chemiluminescence immunoassay market is categorized into consumables and instruments. The repetitive purchase of consumables such as reagents for every test is a major factor driving the growth of the segment. Besides the availability of efficient assays and reagents for diagnostic purposes has propelled its demand among end users.
In 2022, the infectious disease diagnostics segment held the largest share of the chemiluminescence market, by application segment
The chemiluminescence immunoassay market, by application, has been segmented into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, gastroenterology, neurology, respiratory, therapeutic drug monitoring, metabolic disorders, and other applications. The large share of this segment can be attributed to the development and introduction of advanced assays for the diagnosis of different diseases & conditions, and the increase in the population with infectious diseases.
North America dominates the global chemiluminescence immunoassay market
Based on the region, the chemiluminescence immunoassay market is segmented into North America, Europe, Asia Pacific, and Rest of the world. In 2022, North America accounted for the largest share of the chemiluminescence immunoassay market. The large share of North America in this market can be attributed to the increasing prevalence of infectious diseases and cancer and rising healthcare spending, which is highly developed in the US and Canada.
Report Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=26017452
Chemiluminescence Immunoassay Market Dynamics:
Drivers:
- Rising incidence of chronic and infectious diseases across the globe
Restraints:
- High cost of CLIA related products
Opportunities:
- Increasing number of collaborations and partnerships in the CLIA market
Challenges:
- Lack of skilled professionals and aging workforce
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131865271
Recent Developments:
- In May 2023, EUROIMMUN's parent company PerkinElmer's life science and diagnostics business segment, has been rebranded as Revvity.
- In December 2022, Mindray launched CLIA-based assays, IL-6, PCT, and sCD14-S, which have high sensitivity, a wide linearity range, great precision, and good anti-interference ability.
- In December 2022, Sysmex received manufacturing and marketing approval in Japan for the HISCL ?-Amyloid 1-42 Assay Kit and the HISCL ?-Amyloid 1-40 Assay Kit to measure amyloid beta (A?) in the blood.
- In November 2022 Getein Biotech, Inc. launched MAGICL 6000, a compact and innovative chemiluminescence immunoassay analyzer used in mid to high-workflow laboratories
- In June 2022, QuidelOrtho Corporation was formed through a transaction between Quidel Corporation and Ortho Clinical Diagnostics to form a leading in vitro diagnostics company.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Navigating Growth: Chemiluminescence Immunoassay Market Overview, Key Players, and Projections for 2028
In May 2023, EUROIMMUN's parent company PerkinElmer's life science and diagnostics business segment, has been rebranded as Revvity.